This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

This study has been completed.
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: October 15, 2008
Last updated: January 16, 2014
Last verified: January 2014
The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.

Condition Intervention Phase
Myelodysplastic Syndrome Acute Myeloid Leukemia Drug: Ara-C Drug: Mitoxantrone Drug: Etoposide Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • Response to Induction Chemotherapy (CR or PR) [ Time Frame: Day 28-40 ]
    Complete remission (CR): <5% bone marrow blasts with recovery of peripheral blood counts; complete cytogenetic remission, the disappearance of any pre-existing cytogenetic abnormality Partial remission (PR): >5% bone marrow blasts, but less than the pre-treatment blast percentage within the bone marrow Resistant disease (RD): no significant cytoreduction in bone marrow leukemic cells from pre-treatment levels Not evaluable (NE): patients who died during induction chemotherapy or who withdrew from follow-up before assessment could be made

  • Overall Survival [ Time Frame: Up to 2000 days ]
  • Relapse-free Survival [ Time Frame: Up to 2000 days ]
    Relapse is defined as bone marrow blasts >5% if the patient had achieved a complete remission, or the recurrence of any clonal cytogenetic abnormality.

Secondary Outcome Measures:
  • Feasibility of Stem Cell Collection [ Time Frame: 1-5 days from initiation of stem cell collection ]
    Feasibility is the ability to cryopreserve >=2.0 x 10^6 CD34+ cells/kg

  • Numbers of Stem Cells Collected [ Time Frame: 1-5 days from initiation of stem cell collection ]
  • Overall Survival in Patients Undergoing Autologous Stem Cell Transplant [ Time Frame: Up to 817 days ]
  • Disease-free Survival in Patients Undergoing Autologous Stem Cell Transplant [ Time Frame: Up to 883 days ]

Enrollment: 32
Study Start Date: December 2002
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Induction chemotherapy followed by stem cell transplant
Ara-C Mitoxantrone Etoposide Stem cell mobilization Autologous transplant
Drug: Ara-C

Induction: 3000mg/m2 IV infusion for day 1 and day 5

Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)

Other Names:
  • Cytarabine
  • HiDAC
Drug: Mitoxantrone
Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
Drug: Etoposide
Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
Other Name: VP-16


Ages Eligible for Study:   10 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have received cytotoxic chemotherapy,radiation,or a drug known to affect the properties of DNA or cell growth for some condition other than acute myeloid leukemia prior to diagnosis.
  • Patients must have t-MDS/t-AML
  • To be eligible for allogeneic transplantation, patients must have a suitable donor who is HLA compatible.
  • Patients must be over the age of 10.
  • Patients must be reviewed and discussed at the Leukemia and Transplant Conferences of the Section of Hematology/Oncology.

Exclusion Criteria:

  • Patients must not have any other serious medical condition(e.g.uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or infection)
  • Psychiatric condition which would prevent compliance or possibly be worsened by treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00774046

United States, Illinois
The University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Principal Investigator: Lucy Godley, M.D. University of Chicago
  More Information

Responsible Party: University of Chicago Identifier: NCT00774046     History of Changes
Other Study ID Numbers: 11884A
Study First Received: October 15, 2008
Results First Received: December 17, 2012
Last Updated: January 16, 2014

Keywords provided by University of Chicago:
Therapy-related myelodysplastic syndrome/ Therapy -related Acute myeloid leukemia
Myelodysplastic syndrome
Acute myeloid leukemia

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Pathologic Processes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Etoposide phosphate
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 16, 2017